Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 202

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration

Hogerzeil, Hans V, Liberman, Jonathan, Wirtz, Veronika J, Kishore, Sandeep P, Selvaraj, Sakthi, Kiddell-Monroe, Rachel, Mwangi-Powell, Faith N, von Schoen-Angerer, Tido · 2013 · The Lancet

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)62128-x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 39

  1. Di Cesare, 2013, Inequalities in non-communicable diseases and effective responses, Lancet, 10.1016/S0140-6736(12)61851-0 · DOI · Paper page
  2. Cameron, 2009, Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis, Lancet, 373, 240, 10.1016/S0140-6736(08)61762-6 · DOI · Paper page
  3. O'Brien M, Mwangi-Powell F, Adewole I, et al. Improving access to analgesic drugs for patients with cancer in sub-Saharan Africa. Lancet Oncology (in press).
  4. Alleyne, 2013, Embedding of non-communicable diseases in the post-2015 development agenda, Lancet, 10.1016/S0140-6736(12)61806-6 · DOI · Paper page
  5. Hogerzeil, 2006, Human rights and essential medicines: what can they learn from each other?, Bull World Health Organ, 84, 371, 10.2471/BLT.06.031153 · DOI
  6. Perehudoff, 2010, Access to essential medicines in national constitutions, Bull World Health Organ, 88, 800, 10.2471/BLT.10.078733 · doi:10.2471/blt.10.078733
  7. Hogerzeil, 2006, Is access to essential medicines as part of the fulfillment of the right to health enforceable through the courts?, Lancet, 368, 305, 10.1016/S0140-6736(06)69076-4 · doi:10.1016/s0140-6736(06)69076-4
  8. Lim, 2007, Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs, Lancet, 370, 2054, 10.1016/S0140-6736(07)61699-7 · DOI · Paper page
  9. Atun, 2013, Improving responsiveness of health systems to non-communicable diseases, Lancet, 10.1016/S0140-6736(13)60063-X · DOI · Paper page
  10. Bigdeli, 2012, Access to medicines from a health system perspective, Health Policy Plan
  11. Kanavos, 2008, Generic policies: rhetoric versus reality, Euro Observer, 10, 1
  12. Twagirumukiza, 2010, Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines, Trop Med Int Health, 15, 350, 10.1111/j.1365-3156.2009.02453.x · DOI
  13. Caudron, 2008, Substandard medicines in resource-poor settings: a problem that can no longer be ignored, Trop Med Int Health, 13, 1062, 10.1111/j.1365-3156.2008.02106.x · DOI · Paper page
  14. Twagirumukiza, 2009, Influence of tropical climate conditions on the quality of antihypertensive drugs from Rwandan pharmacies, Am J Trop Med Hyg, 81, 776, 10.4269/ajtmh.2009.09-0109 · DOI
  15. Laing, 2001, Ten recommendations to promote improved use of medicines in developing countries, Health Policy Plan, 16, 13, 10.1093/heapol/16.1.13 · DOI · Paper page
  16. Wagner, 2011, Access to care and medicines, burden of health care expenditures and risk protection: results from the World Health Survey, Health Policy, 100, 151, 10.1016/j.healthpol.2010.08.004 · DOI
  17. Frenk, 2012, Universal health coverage: good health, good economics, Lancet, 308, 862, 10.1016/S0140-6736(12)61341-5 · DOI
  18. Reddy, 2011, Towards achievement of universal health care in India by 2020: a call to action, Lancet, 377, 760, 10.1016/S0140-6736(10)61960-5 · DOI · Paper page
  19. Hardon, 2007, Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa, AIDS Care, 19, 658, 10.1080/09540120701244943 · DOI · Paper page
  20. Marquez, 2012, No more disease silos for sub-Saharan Africa, BMJ, 345, e5812, 10.1136/bmj.e5812 · DOI
  21. Gilks, 2006, The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings, Lancet, 368, 505, 10.1016/S0140-6736(06)69158-7 · DOI · Paper page
  22. Ford, 2011, The first decade of antiretroviral therapy in Africa, Global Health, 7, 33, 10.1186/1744-8603-7-33 · DOI
  23. Mills, 2012, Adherence to antiretroviral therapy: supervision or support?, Lancet Infect Dis, 12, 97, 10.1016/S1473-3099(11)70354-1 · DOI
  24. Ford, 2009, Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials, Lancet, 374, 2064, 10.1016/S0140-6736(09)61671-8 · DOI
  25. Wald, 2003, A strategy to reduce cardiovascular disease by more than 80%, BMJ, 326, 1419, 10.1136/bmj.326.7404.1419 · DOI · Paper page
  26. Panchagnula, 2004, Fixed dose combinations for tuberculosis: lessons learned from clinical, formulation and regulatory perspective, Methods Find Exp Clin Pharmacol, 26, 703, 10.1358/mf.2004.26.9.872568 · DOI
  27. Kishore, 2011, Promoting global cardiovascular health: ensuring access to cardiovascular medicines in low- and middle-income countries, J Am Coll Cardiol, 57, 1980, 10.1016/j.jacc.2010.12.029 · doi:10.1016/j.jacc.2010.12.029
  28. Moon, 2011, A win-win solution? A critical analysis of tiered pricing to improve access to medicines in developing countries, Global Health, 7, 39, 10.1186/1744-8603-7-39 · DOI
  29. Downing, 2012, Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise, Arch Intern Med, 172, 724, 10.1001/archinternmed.2012.187 · DOI
  30. Liberman, 2011, Implications of international law for the treatment of cancer: the Single Convention on Narcotic Drugs and the TRIPS Agreement, Public Health, 125, 840, 10.1016/j.puhe.2011.09.032 · doi:10.1016/j.puhe.2011.09.032
  31. Outterson, 2008, Should access to medicines and TRIPS flexibilities be limited to specific diseases?, Am J Law Med, 34, 317, 10.1177/009885880803400208 · DOI
  32. Roderick, 2012, India's patent laws under pressure, Lancet, 380, e2, 10.1016/S0140-6736(12)61513-X · doi:10.1016/s0140-6736(12)61513-x
  33. Waning, 2010, A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries, J Int AIDS Soc, 13, 35, 10.1186/1758-2652-13-35 · DOI
  34. Smith, 2009, Trade, TRIPS, and pharmaceuticals, Lancet, 373, 684, 10.1016/S0140-6736(08)61779-1 · DOI · Paper page
  35. Maxmen, 2012, Trade deal to curb generic drug use, Nature, 489, 16, 10.1038/489016a · doi:10.1038/489016a
  36. Heath, 2011, Seeming virtuous on chronic diseases, BMJ, 343, d4239, 10.1136/bmj.d4239 · doi:10.1136/bmj.d4239
  37. Gale, 2012, Post-marketing studies of new insulins: sales or science?, BMJ, 344, e3974, 10.1136/bmj.e3974 · DOI
  38. Goroff, 2010, Partnerships to provide care and medicine for chronic diseases: a model for emerging markets, Health Aff, 29, 2206, 10.1377/hlthaff.2009.0896 · DOI
  39. Colombo, 2012, Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey, PLoS One, 7, e34974, 10.1371/journal.pone.0034974 · DOI

Cited by

See all 202

Metadata

Authors
Hogerzeil, H. V., Liberman, J., Wirtz, V. J., Kishore, S. P., Selvaraj, S., Kiddell-Monroe, R., Mwangi-Powell, F. N., & von Schoen-Angerer, T.
Venue
The Lancet
Publisher
Elsevier BV
Published
2013-02
Volume
381
Issue
9867
Pages
680-689
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2138490742
Cited by
202
References
6
FWCI
51.20
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. https://app.cochat.ai/papers/10.1016/s0140-6736(12)62128-x
The paper
Hogerzeil, H. V., Liberman, J., Wirtz, V. J., Kishore, S. P., Selvaraj, S., Kiddell-Monroe, R., Mwangi-Powell, F. N., & von Schoen-Angerer, T. (2013). Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. The Lancet. https://doi.org/10.1016/s0140-6736(12)62128-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.